Lead product VSN16R now in Phase II trials
VSN16R a novel orally active small molecule compound that is substantially better tolerated than existing anti-spastic agents. VSN16R does not cause the flaccidity, sedation or other cognitive side-effects that are major disadvantages of other available drugs.
VSN16R is currently in Phase II testing for the relief of spasticity in people with MS. The trial is being carried out at major NHS hospitals in the UK.
Additional information about the Phase II trial of VSN16R for the treatment of spasticity in people with MS can be found by clicking here.
VSN16R has completed its Phase I clinical trial and has demonstrated excellent safety and tolerability. This first in man study of VSN16R enrolled a total of 80 healthy volunteers in a double blind, placebo-controlled, single ascending dose and multiple ascending dose design and food effect study. The study was carried out by Quintiles, the world's leading clinical research organisation.
VSN16R is a non-sedating modulator of nervous system activity that works by opening a potassium channel known as BKCa. The VSN compounds are highly selective BKCa activators and have many other potential therapeutic uses beyond spasticity, including Fragile X Syndrome, glaucoma, noise-induced tinnitus and many other nervous sustem disorders. These new indications are currently under investigation